RecruitingPhase 1 / Phase 2NCT04753970
Neurological
Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy
5
studies recruiting now
as of 7 Sept 2026
11
studies registered in total
as of 7 Sept 2026
3
countries with a recruiting site
as of 7 Sept 2026
27 Mar 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT07497867
Long-term Prospective Study of Korean CADASIL Patients
RecruitingNCT05677880
Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Study
RecruitingNCT05567744
Registry for CADASIL
RecruitingNCT04310098
CADASIL Registry Study
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
Search all Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the gene involved (NOTCH3).
Treatments being studied
3 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 2Adrenomedullin
Phase 2Tocotrienol
Phase 1/2Cilostazol (Cilostazol)
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).